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A B S T R A C T
Purpose
The WHO guidelines on cancer pain management recommend a sequential three-step analgesic
ladder. However, conclusive data are lacking as to whether moderate pain should be treated with
either step II weak opioids or low-dose step III strong opioids.
Patients and Methods
In a multicenter, 28-day, open-label randomized controlled study, adults with moderate cancer pain were
assigned to receive either a weak opioid or low-dose morphine. The primary outcome was the number of
responder patients, deﬁned as patientswith a 20% reduction in pain intensity on the numerical rating scale.
Results
A total of 240 patients with cancer (118 in the low-dose morphine and 122 in the weak-opioid group)
were included in the study. The primary outcome occurred in 88.2%of the low-dosemorphine and in
57.7%of theweak-opioid group (odds risk, 6.18; 95%CI, 3.12 to 12.24; P, .001). The percentage of
responder patients was higher in the low-dose morphine group, as early as at 1 week. Clinically
meaningful ($ 30%) and highly meaningful ($ 50%) pain reduction from baseline was signiﬁcantly
higher in the low-dose morphine group (P , .001). A change in the assigned treatment occurred
more frequently in theweak-opioid group, because of inadequate analgesia. The general condition of
patients, which was based on the Edmonton Symptom Assessment System overall symptom
score, was better in the morphine group. Adverse effects were similar in both groups.
Conclusion
In patients with cancer and moderate pain, low-dose morphine reduced pain intensity signiﬁcantly
compared with weak opioids, with a similarly good tolerability and an earlier effect.
J Clin Oncol 34:436-442. © 2015 by American Society of Clinical Oncology
INTRODUCTION
The WHO guidelines on cancer pain manage-
ment—or palliative care—are based on a
sequential, three-step, analgesic ladder according
to pain intensity: nonopioids (paracetamol or
nonsteroidal anti-inﬂammatory drugs) to mild
pain in step I; weak opioids (eg, codeine or tra-
madol) to mild-moderate pain in step II; and
strong opioids to moderate-severe pain in step
III.1-3 Despite the widespread use of this ladder,
unrelieved pain continues to be a substantial
concern in patients with either solid or hema-
tologic malignancies,4-8 and a common reason is
represented by the inadequacy of analgesic
therapy, which may be inﬂuenced by multiple
factors, including a nonspeciﬁc setting for cancer
pain and opiophobia.4,9,10 Some authors have
questioned the sequential WHO analgesic ladder,
and in particular, the usefulness of step II opioids.9-
11,12 Current international guidelines recognize
that low doses of a step III opioid (eg, morphine
or oxycodone) may be used instead of codeine or
tramadol for patients with mild-moderate
pain,13-16 although such recommendations are
weak, because they have been made on the basis
of three trials with methodologic ﬂaws, low
statistical power, and selection bias.17-19
Our study, called the Early Strong Opioid
Treatment in Cancer Pain: Morphine VersusWeak
Opioids was a randomized controlled multicenter
study designed to evaluate the efﬁcacy and tol-
erability of low doses of morphine in comparison
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with standard doses of weak opioids in the treatment of moderate
cancer pain in opioid-naı¨ve patients.
PATIENTS AND METHODS
A multicenter, 28-day, open-label, randomized controlled trial was per-
formed at 17 Italian oncology centers. The 1:1 random allocation, stratiﬁed
by age (, 75 years v $ 75 years) and participating center, was centralized
using a computer-generated procedure.
The study protocol was approved by the ethics committee of each
participating center and was registered on the National Clinical Trial
Register and with the European Clinical Trials.
Study Population
Patients with cancer who are opioid naı¨ve, with moderate pain
intensity (4-6 on the standard Numerical Rating Scale [NRS], range 0-10)20
were included in the study after screening for eligibility criteria: age . 18
years; Karnofsky performance status of 60% or more; absence of cognitive
impairment or psychiatric illness; and estimated survival of at least
3 months. Pain was related to cancer and to anticancer therapy, and other
additional causes of pain could be recorded. The Edmonton Symptom
Assessment System (ESAS) was used to assess nine symptoms commonly
experienced by patients with cancer during the previous 24 hours: pain,
tiredness, nausea, depression, anxiety, drowsiness, appetite, feelings of well-
being, and shortness of breath. The severity of each symptomwas rated on a
numerical scale of 0 to 10 (0, no symptoms; 10, worst possible severity). The
sum of individual symptom scores, from 0 to 10, corresponds to the ESAS
overall symptom score, ranging from 0 to 90.21-23 The ESAS, validated in the
Italian language,24 was administered to the patients. Opioid-naı¨ve patients
were patients receiving neither opioid analgesics nor chronic opioid anal-
gesics around the clock, at study inclusion. Exclusion criteriawere as follows:
contraindication to opioid use; chronic renal failure (glomerular ﬁltration
rate , 30 mL/min); severe hepatic or respiratory failure; malabsorption
syndrome; uncontrolled diarrhea, nausea, vomiting because of cancer thera-
pies; subileus or intestinal obstruction; radiotherapy or radiometabolic therapy;
current use of investigational drugs; or inability to take oral medications.
Study Treatments and Procedures
Patients were randomly assigned to receive either low-dose oral
morphine (M) or a weak opioid (WO) from randomization until day 28.
The WO group could receive oral formulations of tramadol alone or in
combinations with paracetamol, or codeine in ﬁxed combination with
paracetamol, the only one oral formulation of codeine available in Italy, at
the time of the study, according to the routine clinical practice of each
center, by adhering to a procedure of WO prescription, described in the
study protocol (Data Supplement). This group, regardless of the drug used,
was considered as a whole when compared with the M group. The
minimum effective dose of WO was scheduled for a progressive increase, if
necessary up to the maximum recommended dose: 240 mg/die, or 180 in
ﬁxed combination with paracetamol, for codeine; and 400 mg/die, or 300
mg/die if patients were older than 75 years, for tramadol. The maximal
daily dose of paracetamol was set at 4000 mg/day. The switch from one to
another WO was allowed.
Patients assigned to the M group underwent a 3-day titration phase
with normal-release oral morphine up to 30 mg daily,25 and, thereafter,
continued treatment with slow-release morphine (Data Supplement). Both
the switch to a strong opioid in the WO group and the switch to another
strong opioid in the M group were allowed only when the therapeutic dose
was reached by titration and were considered as an end-point event, at the
end of study observation. Patients were monitored weekly, on days 7, 14,
21, and 28 after randomization. The baseline and weekly control visits
included the following evaluations: pain intensity by NRS, cancer
symptoms with ESAS, Karnofsky performance status, continuation or
switch of assigned analgesic treatment, change of dosage, and adverse
effects associated with treatment. The frequency of adverse effects was
assessed prospectively at every follow-up visit. This included asking the
patients about the presence of vomiting, constipation, dry mouth, itch,
dizziness, somnolence, cognitive impairment, pseudohallucinations,
myoclonic jerks, and other expected opioid-related toxicities.
Outcomes
A patient experiencing a reduction of pain intensity of 20% or more
from baseline was deﬁned as a responder patient,26 and the number of
responder patients at 28 days or at the end of observation, whichever came
ﬁrst, was assumed as the primary end point. The proportion of pain
reduction was calculated by the following formula: (pain intensity at ﬁnal
time2 pain intensity at initial time)/(pain intensity at initial time)3 100.
Secondary outcomes included improvement in physical symptoms and
overall well-being as assessed with ESAS21-23; number of patients with a
clinically meaningful ($ 30%) and highly meaningful ($ 50%) reduction
of pain intensity from baseline27; mean increase of opioid dosage calcu-
lated as opioid escalation index percentage according to the formula
(OMD 2 OSD)/OSD/days 3 100, where OSD is the opioid starting dose
and OMD the opioid maximal dose.26 Type and incidence of adverse
effects, and therapy discontinuation because of adverse effects, were
evaluated at each ambulatory visit.
Statistical Analysis
Assuming as clinically signiﬁcant a 30% increase in response rate in
the M group from an expected 45% in the WO arm, and a power of 80% at
a signiﬁcant level of a two-sided P value of .05, a sample size of 426 patients
(213 per arm) was calculated. After considering an increasingly slower
accrual of patients, possibly corresponding to the publication of recom-
mendations recognizing M as a possible treatment for step II,15 the steering
committee decided to perform an interim analysis when 240 patients were
enrolled (Data Supplement). Therefore, this analysis has been conducted
by intention to treat on the population included in the interim and fol-
lowed up according to the protocol.
Categorical variables are presented as frequencies and proportions
and continuous variables as medians and interquartile ranges (IQRs).
Differences in clinical characteristics were analyzed with the x2 test or
Fishers’ exact test and the Mann-Whitney U test for categorical and
continuous variables, respectively. Binary outcomes were reported as
proportions and were compared using the x2 test, whereas continuous
outcomes were reported as medians (IQRs) and compared with the Mann-
Whitney U test. A multivariate logistic regression model was performed to
estimate the treatment effect adjusting for the effects of other covariates
known to be of prognostic importance, such as pain intensity at baseline,
age, sex, Karnofsky performance status, adjuvant analgesic therapy, rescue
therapy, tumor type, and anticancer treatment. Results were expressed as
odds ratios with 95% CI. A linear mixed model was used to evaluate the
time course of the pain intensity score by study arm. Statistical analysis was
done using SAS software, version 9.3 (SAS Institute, Cary, NC).
RESULTS
Study Population
A total of 240 opioid-naı¨ve patients with cancer withmoderate
pain (NRS, 4 to 6) were enrolled onto the study from 17 centers
(median, 9; IQR, 3 to 14). Of 240 patients, 118 patients (49.2%)
were assigned to low-dose oral morphine (M) and 122 (50.8%)
were assigned to weak opioids (WO).
In this latter group, 103 patients (84.4%) received a ﬁxed
combination of codeine (99 patients) or tramadol (four patients)
with paracetamol; for 19 patients (15.6%), tramadol alone was the
choice. The median initial dosages in the WO group were 150 mg
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(IQR, 150 to 300) for tramadol alone; 1590 mg (IQR, 1590 to
1590), and 950mg (IQR, 594 to 1081) for the combination codeine
+ paracetamol and tramadol + paracetamol, respectively. The
median dose of M, after titration, was 30 mg (IQR, 30 to 30).
The baseline characteristics were well balanced between the
two randomized groups, as listed in Table 1, in which the strict
comparability of symptom severity, assessed with ESAS, is also
evident, with a median (IQR) overall symptom score of 21 (14 to
33) in the WO and 1912,22 in the M arm (Data Supplement).
Outcomes
Of the original randomized cohort of 240 patients, 13 patients
(eight in the M and ﬁve in the WO group) could not be included in
the analysis because they dropped out of the study for various
reasons before the ﬁrst measure of the primary end point (Fig 1).
The primary end point of pain reduction of 20% ormore from
baseline was achieved in 88.2% of patients (97 of 110) in the M
group and in 54.7% of patients (64 of 117) in the WO group (odds
ratio, 6.18; 95% CI, 3.12 to 12.24; P , .001). Full adjustment for
baseline covariates did not modify this result (Table 2).
As shown in Fig 2, the advantage of M over WO was already
evident at the ﬁrst control at 1 week of observation (80.9% v 43.6%;
P, .001) and remained constant at each follow-up (Fig 2A). At the
end of the observation period, a satisfactory pain control was
registered in both groups, althoughwith a statistically and clinically
signiﬁcant advantage for M (median NRS score, 1; IQR, 0 to 2)
compared with WO (median NRS score, 2; IQR, 0 to 4; P = .02; Fig
2B). Moreover, the results of the linear mixed-model analysis to
evaluate the time course of pain intensity score in each group
showed that over time there was a greater reduction in pain
intensity in the group treated with morphine (interaction P = .001;
Fig 2B).
The ﬁndings related to the other measures of outcome are
strictly consistent with the main results. A clinically meaningful
($ 30%) and highly meaningful ($ 50%) pain reduction was
found more frequently in patients treated with M than in those
treated with WO, with proportions and statistical signiﬁcance
mirroring the broader estimate obtained for the primary end point
(Table 2).
The general condition of patients, which was based on the
ESAS overall symptom score, was better in the morphine group
(median score, 10; IQR, 6 to 15) than in the weak-opioid group
(median score, 19; IQR, 10 to 17; P , .001; Table 3).
The patterns of switching between treatments and of dosage
adjustments are also informative on the management sides of pain
control. Forty-one patients (35.0%) in theWO group switched to a
strong opioid and 17 (15.5%) in the M group switched to another
strong opioid (P = .001); over the study period, 60.9% (67 of 110)
of the M group and 40.2% (47 of 117) of the WO group modiﬁed
neither the dosage nor the drug assigned (P = .002). On the other
side, 28.2% (33 of 117) of the WO patients and 13.6% (15 of 110)
of the M patients required a dosage increase (P = .007). The opioid
escalation index (OEI%6 standard deviation) was lower in the M
than in the WO group (4.76 6 6.44 v 8.76 6 6.81; P = .002).
Adverse Events
Both drug treatments were well tolerated. Only ﬁve patients in
each group discontinued their assigned treatment because of
adverse effects or poor tolerability (three and two patients per
group, respectively). No differences in the intensity and frequency
of opioid-related symptoms were observed between the two groups
(Data Supplement).
DISCUSSION
In this multicenter, 28-day, open-label, randomized trial, low-dose
morphine signiﬁcantly reduced pain intensity, as compared with
weak opioids in patients with cancer and moderate pain, as early as
7 days after treatment. Constipation, dizziness, and other opioid-
related adverse effects were not over-represented, in terms of either
intensity or frequency, in the low-dose morphine group. The late
Table 1. Characteristics of Patients at Baseline
Characteristics
Weak Opioids
(N = 122)
Morphine
(N = 118)
Male sex 68 (55.7) 56 (47.5)
Age, years
Median 68 68
Interquartile range 59-74 58-74
Cancer
Solid 108 (88.5) 100 (84.8)
Hematologic 14 (11.5) 18 (15.3)
Current antitumor treatment 61 (50.0) 71 (60.2)
Karnofsky performance status, %
60 9 (7.4) 5 (4.2)
70 48 (39.3) 42 (35.6)
80 28 (23.0) 35 (29.7)
90 23 (18.9) 18 (15.3)
100 14 (11.5) 18 (15.3)
ESAS overall symptom score
Median 21 19
Interquartile range 14-33 12-29
Pain intensity (NRS)
Median 5 5
Interquartile range 4-6 5-6
Cause of pain*
Cancer 117 (95.9) 104 (88.1)
Treatment 8 (6.6) 15 (12.7)
Other† 2 (1.6) 6 (5.1)
Type of pain*
Visceral 69 (56.6) 59 (50.0)
Somatic 62 (50.8) 61 (51.7)
Neuropathic 5 (4.1) 15 (12.7)
Pain characteristics
Incidental pain 38 (31.2) 43 (36.4)
Not incidental 84 (68.9) 75 (63.5)
Previous analgesic therapy 100 (82.0) 98 (83.1)
At ﬁxed times 19 (19.0) 21 (21.4)
As needed 81 (81.0) 77 (78.6)
Rescue therapy (prescription) 105 (86.1) 106 (89.8)
Adjuvant therapy 79 (64.8) 78 (66.1)
Duration of pain, days
Median 30 30
Interquartile range 14-60 15-60
NOTE. Data are presented as No. (%) unless indicated otherwise.
Abbreviations: ESAS, Edmonton Symptom Assessment System; NRS,
Numerical Rating Scale.
*Multiple selection possible.
†Associated conditions recorded as other causes of pain in addition to cancer
and treatment.
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and lower effect of treatment with weak opioids led to a more
frequent switch to step III strong opioids.
In an early retrospective study by Ventafridda and col-
leagues,11 the effectiveness of step II of the WHO method had a
time limit of 30 to 40 days and, for most patients, the shift to step
III was made mainly because of inadequate analgesia rather than
adverse events. In current daily clinical practice, step II is often
bypassed in favor of strong opioids, although the strategy is not
supported by strong scientiﬁc evidence, because it was investigated
by only two randomized controlled studies enrolling only 92 and
54 terminally ill patients, respectively,17,18 and one prospective
study.19 In the study by Marinangeli and colleagues,17 a sig-
niﬁcantly better pain relief was achieved in patients with mild-
moderate pain treated with strong opioids, compared with those
treated with step II opioids, with only nausea more frequent in the
former group, whereas no differences in other opioid-related
symptoms were observed. In a study by Maltoni and col-
leagues,18 patients receiving step III opioids had a signiﬁcant
advantage in terms of a reduction in the number of days with the
worst pain, but more frequently showed grade 3 and 4 anorexia and
constipation. In a prospective study by Mercadante and col-
leagues19 that enrolled only 110 patients with moderate-severe
pain, treatment with low-dose morphine (starting dose of 15 mg/
day and in patients $ 70 years 10 mg/day) was effective and well
tolerated. However, these three studies reported inconclusive
results because of the low number and representativeness of the
patient sample and the low statistical power, leading to a weak
recommendation for either a step II opioid or low doses of a step III
opioid, as an alternative, in international guidelines.14-16 To the
best of our knowledge, our study has provided the ﬁrst formal
proof that, although step II opioids are effective when used for
limited time intervals, low-dose morphine can be usefully
anticipated and can substitute for weak opioids in patients with
cancer and moderate pain, more than half of whom are receiving
active antitumor therapy (Table 1), because of greater efﬁcacy and a
comparable toxicity proﬁle.
Screened
(N = 283)
Enrolled and underwent random assignment
(n = 240)
Assigned to weak opioids treatment
(n = 122)
Assigned to morphine treatment
(n = 118)
Included in the analysis
(n = 117)
Included in the analysis
(n = 110)
Lost to follow-up before a  (n = 5)
 primary end-point
)1 = n( daeD  
  Transferred to another hospital (n = 2)
  Had poor compliance (n = 1)
  Had worsening general  (n = 1)
    condition
Lost to follow-up before a  (n = 8)
 primary end-point
)2 = n( daeD  
  Transferred to another hospital (n = 1)
  Withdrew consent (n = 4)
  Had poor compliance (n = 1)
Refused (n = 7)
Not eligible (n = 36)
Fig 1. Study enrollment, randomization,
and follow-up. All of the participants who
were randomly assigned were included in
the analysis with the exception of the 13
participants who discontinued follow-up
before the primary end point.
Table 2. Outcomes
Outcome
Weak Opioids
(N = 117), No. (%)
Morphine
(N = 110), No. (%)
Odds Ratio
(95% CI) P
Adjusted Odds
Ratio* (95% CI) P
Primary outcome
Responders† 64 (54.7) 97 (88.2) 6.18 (3.12 to 12.24) , .001 6.89 (3.33 to 14.25) , .001
Secondary outcomes
Patients with a meaningful pain reduction‡ 55 (47.0) 91 (82.7) 5.40 (2.92 to 9.97) , .001 5.74 (3.03 to 10.90) , .001
Patients with highly meaningful pain reduction § 49 (41.9) 83 (75.5) 4.27 (2.42 to 7.53) , .001 4.58 (2.52 to 8.33) , .001
*Adjusted by pain intensity at baseline, age, gender, Karnofsky performance score, adjuvant therapy, rescue therapy, cancer type and anticancer treatment.
†Patients with pain intensity reduction at least 20% from baseline.
‡Patients with $ 30% pain intensity reduction from baseline.
§Patients with $ 50% pain intensity reduction from baseline.
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The observed advantages in the clinical outcome coincide with
the doubling of the estimates formulated in the original protocol
and translate into a statistical signiﬁcance (P , .001) of the dif-
ference, in the primary end point, already in a population which is
a half of the one planned, in the original statistical design. The
clinical reliability and signiﬁcance are conﬁrmed by the coinci-
dence of similarly statistically signiﬁcant ﬁndings in the secondary
end points (Table 2), and the ESAS results (Table 3). The minimal
clinical difference for improvement and deterioration of each of
the nine ESAS symptoms is one point or more.28 When the
magnitude of symptom changes was assessed by ESAS in the two
groups, treatment with low-dose morphine was associated with a
signiﬁcant improvement in either physical or emotional symp-
toms, providing a further argument in favor of its use in opioid-
naı¨ve patients with cancer with moderate pain.
Support of the ﬁndings could be seen in the consistency
between crude estimates and the results obtained in the fully
adjusted multivariate analysis, which could, on the contrary, be
rather sensible to the instability associated with the small numbers
of the population.
Despite conﬁdence in the outcome of the study, we are aware
of aspects of the trial, which could be considered structural, more
than formal, weaknesses, namely, the lower and too long accrual of
patients, assessed in an exploratory interim analysis which became
(because of the surprising available evidence) a, somehow, man-
datory stopping rule; the absence of pharmacologic quantiﬁcation
of rescue prescriptions; the open-label design. Relevant to this,
opiophobia caused by the reluctance of patients and/or their
families to accept strong opioids is a well-described cause of
undertreatment of pain and may result in a low compliance with
the recommended doses.4 A double-blind study was not possible
because the WO group potentially could have received three dif-
ferent drugs/oral formulations, according to potentially different
clinical practice in each of the 17 centers. The open-label design
also had the advantage of allowing physicians to titrate the
morphine to the optimal dose on a personalized basis and also to
rotate to the alternative opioid rapidly in case of uncontrolled pain
and/or adverse effects. The choice to perform a nonproﬁt study was
an obvious limitation for a double-blind design. It is, however,
reasonable to see those weaknesses also against either the overall
background given in the introduction, or the mandatory pragma-
tism of this trial, which was promoted by a fully independent group
of clinicians, with no external ﬁnancial support. Unfortunately, the
best type of strong opioid has not been established and themorphine
equivalent daily doses were not available; therefore, more research is
needed to compare the most commonly used m-opiod agonists such
as morphine, hydromorphone, fentanyl, and methadone as ﬁrst-line
opioids, in terms of both pain intensity and adverse effects. It is also
recommended that future studies prospectively determine the
morphine equivalent daily dose.
In conclusion, our study demonstrated that compared with
step II opioids, low-dose morphine provided an earlier and a more
adequate level of analgesia for moderate cancer pain, with a fairly
good tolerability proﬁle and a positive impact on overall well-
being. In most countries, strong opioids are highly regulated, and
oncologists, family physicians, and internists may prefer to pre-
scribe weak opioids because of lower regulatory requirements,
including special prescriptions forms.29-31 However, our data show
that this intermediate step may be less effective and more
expensive. The current WHO recommendation has the three-step
pain ladder as the basis for treatment of cancer pain. New
guidelines, including that by the EAPC, describe a two-step
No. at risk
Weak opioid  84 75 66
Morphine  92 87 82
87.3
† †**
43.6
51.3 53 54.7
80.9*
88.2 88.2* * *
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Treatment .06
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Fig 2. Responder patients and pain intensity (numerical rating scale [NRS]) at different follow-up times by treatment group. (A) Percentage of responder patients (who
achieved$ 20% pain reduction from baseline) at each follow-up. The P value is for the between-group comparison performed using the x2 test. (B) Pain intensity evaluated
using the NRS at each follow-up. Data are shown as median and interquartile range. A linear mixed mode for repeated measurements was done on pain intensity score.
*P , .001, †P = .02 by Mann-Whitney U test.
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approach as an alternative.15 To abolish the second step will
simplify treatments and perhaps give patients with cancer better
pain control. Whether the ﬁndings of this study, which are in favor
of starting directly with a step three opioid, may contribute to
changing the WHO guidelines must be conﬁrmed by other phase
IIIb/phase IV studies.
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Table 3. ESAS at End of Study
ESAS Item Weak Opioids Morphine P
Pain 4 (1-6) 1 (0-3) , .001
Tiredness 3 (2-6) 2 (1-3) , .001
Nausea 1 (0-3) 1 (0-1) .03
Depression 2 (1-4) 1 (0-2) , .001
Anxiety 2 (0-4) 1 (0-2) , .001
Drowsiness 3 (1-4) 1 (0-2) , .001
Appetite 2 (1-5) 1 (0-2) , .001
Well-being 3 (1-5) 1 (0-2) , .001
Shortness of breath 0 (0-1) 0 (0-0) .01
ESAS overall symptom score 19 (10-17) 10 (6-15) , .001
NOTE. Data are presented as median (interquartile range).
Abbreviations: ESAS, Edmonton Symptom Assessment System.
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GLOSSARY TERMS
palliative care: care designed to address symptoms and maximize quality of life, regardless of patient prognosis
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